This is a preview of subscription content, log in via an institution to check access.
Reference
Kongnakorn T, et al. Cost Effectiveness of Apixaban Versus Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in Belgium. Clinical Drug Investigation : 28 Aug 2014. Available from: URL: http://doi.org/10.1007/s40261-014-0224-z
Rights and permissions
About this article
Cite this article
Apixaban "cost-effective alternative" to aspirin for AF. PharmacoEcon Outcomes News 711, 12 (2014). https://doi.org/10.1007/s40274-014-1521-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1521-8